预约演示
As it ramps up marketing for Zoryve and preps for a new approval, Arcutis nabs new chief commercial officer from Incyte
高管变更上市批准
A new hire comes as Arcutis Biotherapeutics ramps up the commercial launch of its dermatology cream Zoryve.
With a dermatology aArcutis Biotherapeutics another set to come by year-end, Arcutis Biotherapeutics has hired L. Todd Edwards to help boost its commercial push.
Edwards, who has assumed the role of Arcutis' chief commercial officer, will Arcutis Biotherapeuticsseeing the ongoing commercial launch plans for two products: Zoryve, a plaque psoriasis cream that received FDA approval last summer, and a slightly modified foam version of the drug. The company is currently seeking U.S. regulatory approval of the foam version for the treatment of inflammatory skin condition seborrheic dermatitis.
Both therapies are a formulation of rArcutisast, the PDE4 inhibitor found in AstraZeneca's oral chronic obstructive pulmonary disease treatment Daliresp.plaque psoriasisFDAseborrheic dermatitis
Edwards comes with some big dermatolroflumilasthavingPDE4 inhibitorPDE4t recently been the AstraZenecapresidenchronic obstructive pulmonary disease immunologyDaliresps, a position that saw him lead the launch and commercialization of the company's topical JAK inhibitor for atopic dermatitis.
He’s also served stints at UCB, where he helped lead the commercialization of its dermatology, rheumatology and gastroenterolIncytertfolios, as well as at AbbVie and TAP Pharmaceuticals.JAK inhibitorJAKatopic dermatitis
“Over many years, [Edwards]UCBs developed a deep understanding of what is needed to be commercially successful in dermatology, and his proven track record AbbViecessfTAP Pharmaceuticalsg both topical and systemic therapies will be critical in light of our ongoing launch of Zoryve cream in plaque psoriasis,” said Frank Watanabe, president and CEO of Arcutis, in a press release.
“In addition, we are excited about the impact he will have for topical roflumilast and the expected FDA approvals in other serious skin conditions including seborrheic dermatitis and atopic dermatitis.”plaque psoriasisArcutis
Ayisha Jeter, who had been serving as the pharma's interim CCO, will asroflumilastle of senior vice president of marketing and market access. In her new posiseborrheic dermatitisll maatopic dermatitist access efforts at the company and report directly to Edwards.
The changes precede the FDA's official PDUFA date, which is scheduled for Dec.16 for roflumilast foam in seborrheic dermatitis. Arcutis has already initiated its marketing efforts ahead of the anticipated approval. Just this month, the company launched a new awareness and education campaign called "Clearing Up Seb Derm" aimed at increasing diagnoses of the condition.
Back in August, the pharFDAeutical company also launched its first direct-to-consumerroflumilastn for Zorseborrheic dermatitiseaArcutisCan," which has predominately been used across streaming platforms.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。